Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays

Journal of Pharmaceutical and Biomedical Analysis

Volumn 125, Issue , 2016, Pages 62-67

  Bian, Sumin ^a   Stappen, Thomas Van ^a   Baert, Filip ^b   Compernolle, Griet ^a   Brouwers, Els ^a   Tops, Sophie ^a   Vries, Annick de ^c   Rispens, Theo ^d   Lammertyn, Jeroen ^e   Vermeire, Séverine ^f   Gils, Ann ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b Department of Gastroenterology ^*  (Belgium)

^c CENTRAL LABORATORY   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Adalimumab; Antibodies; Monoclonal; Therapeutic drug monitoring; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; GOLIMUMAB; INFLIXIMAB; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; CROSS REACTION; DRUG BINDING; DRUG BINDING SITE; DRUG DETERMINATION; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYBRIDOMA; MEASUREMENT ACCURACY; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; SERODIAGNOSIS;

ADALIMUMAB; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEUTRALIZATION TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84961223493     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2016.03.029     Document Type: Article

References (27)

1. Sandborn W.J., Van Assche G., Reinisch W. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265.
2. Colombel J.F., Sandborn W.J., Rutgeerts P. Adalimumab for maintenance of clinical response and remission in patients with crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
3. Chen Y.F., Jobanputra P., Barton P., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 2006, 10. (Executive summary).
4. Gladman D.D., Mease P.J., Ritchlin C.T. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthr. Rheumatol. 2007, 56:476-488.
5. van der Heijde D., Kivitz A., Schiff M.H. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthr. Rheum. 2006, 54:2136-2146.
6. Colombel J.F., Sandborn W.J., Rutgeerts P. Adalimumab for maintenance of clinical response and remission in patients with crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
7. Baert F., Glorieus E., Reenaers C. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J. Crohns Colitis 2013, 7:154-160.
8. Gisbert J.P., Marín A.C., McNicholl A.G., Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment. Pharmacol. Ther. 2015, 41:613-623.
9. Van Schie K.A., Hart M.H., de Groot E.R. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann. Rheum. Dis. 2014, 74:311-314.
10. Karmiris K., Paintaud G., Noman M. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
11. Ungar B., Levy I., Yavne Y., et al. P503 Infliximab and adalimumab serum levels predict probability of mucosal healing. J. Crohns Colitis 2015, S330-S331.
12. Radstake T.R.D.J., Svenson M., Eijsbouts A.M. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 2009, 68:1739-1745.
13. Chen D.Y., Chen Y.M., Tsai W.C. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann. Rheum. Dis. 2015, 74:e16.
14. Mazor Y., Almog R., Kopylov U. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment. Pharmacol. Ther. 2014, 40:620-628.
15. Van der Valk M.E., Mangen M.J.J., Leenders M. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014, 63:72-79.
16. Krieckaert C.L.M., Nair S.C., Nurmohamed M.T. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann. Rheum. Dis. 2015, 74:361-368.
17. Wang S.L., Hauenstein S., Ohrmund L. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J. Pharm. Biomed. Anal. 2013, 78-79:39-44.
18. Eng G.P., Bendtzen K., Bliddal H. Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. Arthritis 2015, 2015:784825.
19. Galfre G., Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 1981, 73:3-46.
20. Nakane P.K., Kawaoi A. Peroxidase-labeled antibody: a new method of conjugation. J. Histochem. Cytochem. 1974, 22:1084-1091.
21. Van Stappen T., Brouwers E., Tops S. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther. Drug Monit. 2015, 37:1-19.
22. Vande Casteele N., Buurman D.J., Sturkenboom M.G.G., et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment. Pharmacol. Ther. 2012, 36:765-771.
23. Pouw M.F., Krieckaert C.L., Nurmohamed M.T. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann. Rheum. Dis. 2015, 74:513-518.
24. Gils A., Vande Casteele N., Poppe R., et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther. Drug Monit. 2014, 36:669-673.
25. Van Schouwenburg P.A., Kruithof S., Votsmeier C. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J. Biol. Chem. 2014, 289:34482-34488.
26. Van Stappen T., Lu J.D., Bloemen M., et al. Transferability of antibody pairs from ELISA to fiber optic surface plasmon resonance for infliximab detection. Proc. SPIE 2015, Optical Fibers and Sensors for Medical Diagnostics and Treatment Applications XV, 931705. 10.1117/12.2077684.
27. Gils A., Van Stappen T., Dreesen E., Storme R., Vermeire S., Declerck P.J. Harmonisation of infliximab and anti-infliximab assays facilitates the comparison between originator and biosimilars in clinical samples. Inflamm. Bowel Dis. 2016, 22:969-975.